Jardiance
Jardiance pulls ahead of Forxiga with heart failure approval in EU
Phil Taylor
AstraZeneca, Boehringer Ingelheim, Eli Lilly, Entresto, heart failure, Jardiance, Novartis
0 Comment
Stage set for Jardiance to become universal heart failure drug
Phil Taylor
AstraZeneca, Boehringer Ingelheim, Eli Lilly, Farxiga, heart failure, Jardiance
0 Comment
Jardiance gets parity with Farxiga in US as FDA clears use in heart failure
Phil Taylor
AstraZeneca, Boehringer Ingelheim, cardiology, Eli Lilly, Farxiga, fda, heart failure, Jardiance, regulatory approval
0 Comment
News/ News/ Sales and Marketing
AZ gets European approvals for Forxiga in chronic kidney disease
Phil Taylor
AstraZeneca, Boehringer Ingelheim, chronic kidney disease, Eli Lilly, EU, Farxiga, Forxiga, Jardiance, UK
0 Comment
Boehringer, Lilly hail Jardiance data in hard-to-treat heart failure
Phil Taylor
AstraZeneca, Boehringer Ingelheim, Eli Lilly, Entresto, Farxiga, heart failure, Jardiance, Novartis
0 Comment
News/ News/ Sales and Marketing
AZ closes in Forxiga kidney disease label in EU after nod from CHMP
Phil Taylor
AstraZeneca, Boehringer Ingelheim, CHMP, chronic kidney disease, Eli Lilly, Farxiga, Forxiga, Jardiance
0 Comment
News/ News/ Sales and Marketing
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance
Phil Taylor
AstraZeneca, Boehringer Ingelheim, cardiology, Eli Lilly, Farxiga, heart failure, Jardiance
0 Comment
AstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDA
Phil Taylor
AstraZeneca, Boehringer Ingelheim, chronic kidney disease, Eli Lilly, Farxiga, fda, Jardiance, nephrology
0 Comment